Suppr超能文献

[肾被膜下移植法(SRCA)的实验研究——采用免疫抑制策略]

[An experimental study on SRCA (subrenal capsule assay)--using immunosuppressive maneuvers].

作者信息

Kikuchi H, Asamura M, Gamoh M, Matsushita T, Wakui A, Takahashi T

机构信息

Dept. of Clinical Cancer Chemotherapy, Tohoku University.

出版信息

Gan To Kagaku Ryoho. 1988 Aug;15(8):2257-63.

PMID:3044274
Abstract

Six-day SRCA using normal mice developed by Bogden et al. is one of the most promising methods for in vivo chemosensitivity tests. However, this method has a problem on the influence of the host reaction during six days. Therefore, we examined the tumour growth kinetics, host reaction and expression of antitumor effect on three immunosuppressive maneuvers; cyclophosphamide (EX), cyclosporin A (CSA), and total body irradiation (TBI). The tumour diameter increased until day 16 in EX and CSA-treated groups and day 10 in TBI-treated group, but the results of the histological examination showed that tumour cells were preserved in tissue on day 14 in CSA-treated group and day 6 in EX and TBI-treated groups. These results were supported by flow cytometrical analysis. The autoradiogram using 3H-TdR showed that labelling index of the tumour cells was not affected by these immunosuppressive maneuvers. From the investigation of the antitumour activity of adriamycin and mitomycin C, it was suggested that the 12-day assay was suitable if nude mice were used in SRCA, and six-day assay, if EX-treated normal mice were used. In CSA-treated group, toxicity of anticancer drugs was manifested than usual.

摘要

Bogden等人开发的使用正常小鼠的六日短期体内化疗药敏试验(SRCA)是最有前景的体内化疗药敏试验方法之一。然而,该方法存在六日期间宿主反应影响的问题。因此,我们研究了三种免疫抑制手段(环磷酰胺(EX)、环孢素A(CSA)和全身照射(TBI))对肿瘤生长动力学、宿主反应和抗肿瘤作用表达的影响。在EX和CSA治疗组中,肿瘤直径在第16天前增加,在TBI治疗组中在第10天前增加,但组织学检查结果显示,CSA治疗组在第14天、EX和TBI治疗组在第6天肿瘤细胞仍保留在组织中。这些结果得到了流式细胞术分析的支持。使用3H-TdR的放射自显影片显示,肿瘤细胞的标记指数不受这些免疫抑制手段的影响。从阿霉素和丝裂霉素C的抗肿瘤活性研究来看,提示如果在SRCA中使用裸鼠,12日试验合适;如果使用EX处理的正常小鼠,则6日试验合适。在CSA治疗组中,抗癌药物的毒性比平常更明显。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验